知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

35 records (took 0.022 seconds)

    BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS
    3.
    发明申请
    BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS 有权
    BRACHODILATTING BETA-AGONIST组合物和方法

    公开(公告)号：US20070166235A1

    公开(公告)日：2007-07-19

    申请号：US11688450

    申请日：2007-03-20

    Applicant: Partha Banerjee ,  Imtiaz Chaudry ,  Stephen Pham

    Inventor： Partha Banerjee ,  Imtiaz Chaudry ,  Stephen Pham

    IPC: A61K31/138 ,  A61K9/12

    CPC classification number: A61K9/0078 ,  A61K31/167 ,  A61K31/205 ,  A61K31/46

    Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

    Abstract translation: 提供支气管扩张剂组合物和方法。 组合物用于作为喷雾气雾剂的给药。 在某些实施方案中，组合物含有福莫特罗或其衍生物。 还提供了使用本文提供的组合物治疗，预防或改善支气管收缩性疾病的一种或多种症状的方法。

    Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
    5.
    发明授权
    Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease 有权
    沙丁胺醇和异丙托溴铵吸入溶液，缓解慢性阻塞性肺疾病症状的系统，试剂盒和方法

    公开(公告)号：US06632842B2

    公开(公告)日：2003-10-14

    申请号：US10162460

    申请日：2002-06-03

    Applicant: Imtiaz Chaudry ,  Partha Banerjee

    Inventor： Imtiaz Chaudry ,  Partha Banerjee

    IPC: A61K31135

    CPC classification number: A61K9/0078 ,  A61K31/135

    Abstract: The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

    Abstract translation: 本发明涉及用于缓解慢性阻塞性肺疾病（COPD）患者支气管痉挛的双支气管扩张剂吸入溶液，系统，试剂盒和方法。 在一个替代实施方案中，本发明的溶液是用于患有COPD的患者的预包装的，无菌的，预混合的，预测量的单一单位剂量的沙丁胺醇和异丙托溴铵。 本溶液可以不含抗微生物防腐剂，例如苯扎氯铵。 在另一个替代实施方案中，本发明的溶液包含约2.50mg沙丁胺醇和约0.50mg异丙托溴铵。

    Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same
    6.
    发明申请
    Inhalable Formulations For Treating Pulmonary Hypertension And Methods Of Using Same 审中-公开
    用于治疗肺动脉高压的可吸入制剂及其使用方法

    公开(公告)号：US20110265786A1

    公开(公告)日：2011-11-03

    申请号：US13020429

    申请日：2011-02-03

    Applicant: Imtiaz Chaudry

    Inventor： Imtiaz Chaudry

    IPC: A61M11/00 ,  A61K31/40 ,  A61P11/00 ,  A61K31/472 ,  A61K31/405 ,  A61K31/403 ,  A61K31/55 ,  A61K31/675

    CPC classification number: A61K9/0078 ,  A61K31/00 ,  A61K31/401 ,  A61K31/404 ,  A61K31/472 ,  A61K31/55 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/675 ,  A61K38/556 ,  A61K45/06

    Abstract: The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.

    Abstract translation: 本发明涉及用于治疗哺乳动物（例如人）中的肺动脉高压的可吸入制剂，其中所述制剂包含至少一种高血压减轻剂，包括但不限于血管紧张素转换酶抑制剂，血管紧张素受体阻断剂， β-阻滞剂，钙通道阻滞剂或血管扩张剂，或其任何组合。 本发明的制剂可以是溶液或悬浮液，并且优选适于通过雾化进行给药。 本发明还涉及用于治疗患有肺动脉高压的哺乳动物的方法和试剂盒。

    Fluticasone propionate nasal pharmaceutical formulations and methods of using same
    7.
    发明授权
    Fluticasone propionate nasal pharmaceutical formulations and methods of using same 有权
    丙酸氟替卡松鼻制剂及其使用方法

    公开(公告)号：US07972626B2

    公开(公告)日：2011-07-05

    申请号：US11250220

    申请日：2005-10-14

    Applicant: Imtiaz Chaudry

    Inventor： Imtiaz Chaudry

    IPC: A61K9/14 ,  A61K9/12 ,  A61K9/00 ,  A61K31/56

    CPC classification number: A61K31/573 ,  A61K9/0043 ,  A61K9/10 ,  A61K31/56 ,  A61K31/57 ,  A61K31/7048 ,  A61L2/0035 ,  A61K2300/00

    Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is fluticasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is fluticasone propionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.

    Abstract translation: 本文公开了包含具有特定粒度分布特性的药物的鼻内药物制剂。 当鼻内施用时，这种特征提供增加的生物利用度，增加的药效或延长治疗效果。 本发明的制剂可以包含一种或多种具有特定粒度分布特征的皮质类固醇。 在优选的实施方案中，皮质类固醇是氟替卡松或其药学上可接受的衍生物，用于治疗一种或多种鼻炎症状。 优选地，药物物质是丙酸氟替卡松。 本文的制剂可以作为适于通过鼻内途径吸入的水性悬浮液提供。

    NASAL PHARMACEUTICAL FORMULATIONS AND METHODS OF USING THE SAME
    8.
    发明申请
    NASAL PHARMACEUTICAL FORMULATIONS AND METHODS OF USING THE SAME 审中-公开

    公开(公告)号：US20080050442A1

    公开(公告)日：2008-02-28

    申请号：US11931380

    申请日：2007-10-31

    Applicant: Imtiaz Chaudry

    Inventor： Imtiaz Chaudry

    IPC: A61K9/14 ,  A61K31/56 ,  A61P27/00

    CPC classification number: A61K31/573 ,  A61K9/0043 ,  A61K9/10 ,  A61K31/56 ,  A61K31/57 ,  A61K31/7048 ,  A61L2/0035 ,  A61K2300/00

    Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.

    Formulations and methods for treating rhinosinusitis
    10.
    发明申请
    Formulations and methods for treating rhinosinusitis 有权
    治疗鼻鼻窦炎的制剂和方法

    公开(公告)号：US20050180925A1

    公开(公告)日：2005-08-18

    申请号：US11078263

    申请日：2005-03-12

    Applicant: Imtiaz Chaudry

    Inventor： Imtiaz Chaudry

    IPC: A61K9/00 ,  A61K9/10 ,  A61K31/496 ,  A61K31/56 ,  A61K31/57 ,  A61K31/573 ,  A61K31/7048 ,  A61L2/00 ,  A61P11/02 ,  A61K9/14 ,  A61L9/04

    CPC classification number: A61K31/496 ,  A61K9/0043 ,  A61K9/10 ,  A61K31/56 ,  A61K31/57 ,  A61K31/573 ,  A61K31/7048 ,  A61L2/0035 ,  A61L2/07 ,  A61K2300/00

    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including but not limited to, bacterial-induced, viral-induced and/or fungus-induced rhinosinusitis in mammals, and/or rhinosinusitis not induced by an infective agent, such as bacteria, fungus or virus. In one embodiment, the formulation of the present invention comprises an anti-inflammatory agent (e.g. fluticasone propionate) having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.

    Abstract translation: 本发明涉及用于治疗或预防鼻鼻窦炎的方法和制剂，包括但不限于哺乳动物中的细菌诱导的，病毒诱导的和/或真菌诱导的鼻鼻窦炎，和/或不被感染剂如细菌引起的鼻鼻窦炎， 真菌或病毒。 在一个实施方案中，本发明的制剂包含具有特定粒度分布曲线的抗炎剂（例如丙酸氟替卡松）。 制剂还可以包含抗真菌剂，抗生素或抗病毒剂。

Patent Agency Ranking